The Oncology Institute, Inc.

NasdaqCM:TOI Stock Report

Market Cap: US$419.8m

Oncology Institute Management

Management criteria checks 2/4

Oncology Institute's CEO is Dan Virnich, appointed in Jun 2023, has a tenure of 2.42 years. total yearly compensation is $1.12M, comprised of 42.5% salary and 57.5% bonuses, including company stock and options. directly owns 0.5% of the company’s shares, worth $2.10M. The average tenure of the management team and the board of directors is 1.1 years and 4 years respectively.

Key information

Dan Virnich

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage42.47%
CEO tenure2.4yrs
CEO ownership0.5%
Management average tenure1.1yrs
Board average tenure4yrs

Recent management updates

Recent updates

Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 26% Lower

Sep 11
Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 26% Lower

The Oncology Institute: A Promising Company In A Growing Sector

Aug 19

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company

Jul 15
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company
User avatar

Value Based Care Contracts Will Unlock Future Oncology Demand

New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market.

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb

Apr 18
A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb

Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower

Mar 04
Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company

Jan 18
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

Jul 19
A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 05
The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Mar 21
Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

Mar 05
Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Nov 10
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

CEO Compensation Analysis

How has Dan Virnich's remuneration changed compared to Oncology Institute's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$54m

Mar 31 2025n/an/a

-US$53m

Dec 31 2024US$1mUS$475k

-US$53m

Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$60m

Dec 31 2023US$808kUS$455k

-US$68m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$50m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$3mUS$446k

US$68k

Sep 30 2022n/an/a

-US$1m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

US$6m

Dec 31 2021US$8mUS$263k

-US$11m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$419kUS$214k

-US$14m

Compensation vs Market: Dan's total compensation ($USD1.12M) is below average for companies of similar size in the US market ($USD2.33M).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Virnich (46 yo)

2.4yrs
Tenure
US$1,118,358
Compensation

Dr. Daniel Virnich, also known as Dan, M.D., M.B.A., FACHE, is Chief Executive Officer of The Oncology Institute Inc. since June 2023 and serves as its Executive Director since June 13, 2024. He served as...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Virnich
CEO & Executive Director2.4yrsUS$1.12m0.50%
$ 2.1m
Yale Podnos
Chief Medical Officer4yrsUS$610.33k0.051%
$ 212.1k
Robert Carter
Chief Financial Officer1.1yrsno data0.022%
$ 92.2k
Austin Lee
VP of Accounting & Controllerless than a yearno datano data
Kristin England
Chief Administrative Officerless than a yearno data0.10%
$ 440.2k
Mark Hueppelsheuser
General Counsel10.8yrsno datano data
Jordan McInerney
Chief Development Officer1.6yrsno datano data
Stephen Cella
Senior Vice President of Financeless than a yearno datano data
Jeffrey Langsam
Chief Clinical Officerless than a yearno datano data
1.1yrs
Average Tenure
46yo
Average Age

Experienced Management: TOI's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Daniel Virnich
CEO & Executive Director1.4yrsUS$1.12m0.50%
$ 2.1m
Mark Pacala
Independent Director3.2yrsUS$82.75k0.19%
$ 785.6k
Bradford Hively
Vice Chairman4yrsUS$81.82k0.49%
$ 2.1m
Anne McGeorge
Independent Chairman4yrsUS$83.68k0.14%
$ 571.8k
Gabe Ling
Director3.2yrsUS$81.20k0.074%
$ 310.0k
Mohit Kaushal
Independent Director5.7yrsUS$83.68k0.15%
$ 637.8k
Karen Marie Johnson
Independent Director4yrsUS$83.06k0.16%
$ 679.8k
4.0yrs
Average Tenure
63yo
Average Age

Experienced Board: TOI's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/04 20:45
End of Day Share Price 2025/11/04 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Oncology Institute, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
David LarsenBTIG
Alexander DraperGuggenheim Securities, LLC